Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, AL, USA.
Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, AL, USA; Department of Biostatistics, University of Alabama at Birmingham, Birmingham, AL, USA.
Mayo Clin Proc. 2024 Feb;99(2):271-282. doi: 10.1016/j.mayocp.2023.09.016. Epub 2024 Jan 6.
To evaluate the contemporary trends of lipid concentrations, cholesterol evaluation, hypercholesterolemia awareness, and statin use among individuals with severe dyslipidemia (low-density lipoprotein cholesterol [LDL-C] level ≥190 mg/dL) between 2011 and 2020.
This serial cross-sectional analysis included nonpregnant adults ≥20 years of age from the National Health and Nutrition Examination Survey between 2011 and 2020. Age-adjusted weighted trends of LDL-C, triglycerides, cholesterol evaluation in the past 5 years, hypercholesterolemia awareness, and documented statin use among individuals with severe dyslipidemia were estimated.
Among 24,722 participants included, the prevalence of severe dyslipidemia was 5.4% (SE: 0.2%) which was stable across the study period (P=.78). Among individuals with severe dyslipidemia (mean age: 55.3 [SE: 0.7] years; 52.2% females; 68.8% non-Hispanic White), LDL-C (224.3 [SE: 4.2] mg/dL in 2011-2012 to 224.2 [SE: 4.6] mg/dL in 2017-2020; P =.83), and triglyceride (123.3 [SE: 1.1] mg/dL in 2011-2012 to 101.8 [SE: 1.1] mg/dL in 2017-2020; P=.13), levels remained stable from 2011 to 2020. The rates of cholesterol evaluation in the past 5 years (72.0% [SE: 5.7%] in 2011-2012 to 78.0% [SE: 4.8%] in 2017-2020; P=.91), hypercholesterolemia awareness (48.1% [SE: 5.5%] in 2011-2012 to 51.9% [SE: 5.8%] in 2017- 2020; P=.77), and documented statin use (34.7% [SE: 4.5%] in 2011-2012 to 33.4% [SE: 4.0%] in 2017-2020; P=.28) remained stagnant in individuals with severe dyslipidemia between 2011 and 2020.
Among individuals with severe dyslipidemia, cholesterol evaluation and hypercholesterolemia awareness rates were stable at ∼75% and ∼50% in the past decade. Only ∼34% of individuals with severe dyslipidemia took statins between 2011 and 2020, which likely contributed to the stable LDL-C levels noted across the study period. Further investigations into the determinants of statin use and adherence to statins are needed.
评估 2011 年至 2020 年间严重血脂异常(低密度脂蛋白胆固醇[LDL-C]水平≥190mg/dL)患者的脂质浓度、胆固醇评估、高胆固醇血症知晓率和他汀类药物使用的当代趋势。
本系列横断面分析纳入了 2011 年至 2020 年期间国家健康和营养检查调查中的非妊娠≥20 岁成年人。估计了严重血脂异常患者中 LDL-C、甘油三酯、过去 5 年胆固醇评估、高胆固醇血症知晓率和有记录的他汀类药物使用的年龄调整加权趋势。
在 24722 名参与者中,严重血脂异常的患病率为 5.4%(SE:0.2%),在整个研究期间保持稳定(P=.78)。在严重血脂异常患者中(平均年龄:55.3[SE:0.7]岁;52.2%为女性;68.8%为非西班牙裔白人),LDL-C(2011-2012 年为 224.3[SE:4.2]mg/dL,2017-2020 年为 224.2[SE:4.6]mg/dL;P=.83)和甘油三酯(2011-2012 年为 123.3[SE:1.1]mg/dL,2017-2020 年为 101.8[SE:1.1]mg/dL;P=.13)水平从 2011 年到 2020 年保持稳定。过去 5 年胆固醇评估率(2011-2012 年为 72.0%[SE:5.7%],2017-2020 年为 78.0%[SE:4.8%];P=.91)、高胆固醇血症知晓率(2011-2012 年为 48.1%[SE:5.5%],2017-2020 年为 51.9%[SE:5.8%];P=.77)和有记录的他汀类药物使用(2011-2012 年为 34.7%[SE:4.5%],2017-2020 年为 33.4%[SE:4.0%];P=.28)在严重血脂异常患者中在过去十年中保持稳定。
在严重血脂异常患者中,胆固醇评估和高胆固醇血症知晓率在过去十年中分别稳定在约 75%和 50%左右。2011 年至 2020 年间,只有约 34%的严重血脂异常患者使用了他汀类药物,这可能是研究期间 LDL-C 水平稳定的原因之一。需要进一步研究他汀类药物使用的决定因素和他汀类药物的依从性。